Mizuho Begins Coverage on AveXis (AVXS)

Stock analysts at Mizuho started coverage on shares of AveXis (NASDAQ:AVXS) in a research report issued on Monday. The brokerage set a “buy” rating and a $147.00 price target on the stock. Mizuho’s price target would suggest a potential upside of 31.37% from the stock’s previous close.

The analysts wrote, “We expect a pre-BLA meeting in 2Q/3Q18, and potential regulatory approval in 2019 for type 1 SMA. We also see additional upside for AVXS-101 in SMA type 2 patients. KeyPoints Gene therapy is coming of age. After years of advancements and discovery in the field of gene therapy, we believe a number of companies are on the cusp of gaining approval for these novel one-time treatments. We see strong potential for leading candidate products and take confidence from the recent unanimous FDA approval of Spark’s (ONCE, Buy, $79 PT) Luxturna. A significant opportunity for gene therapy in the treatment of SMA. With approximately 60% of the incident SMA population affected by type 1 and limited treatment options, AveXis’ lead product candidate AVXS-101 could have a substantial impact. Given strong data from a recent phase 1 trial, we believe AVXS-101 could capture a significant market share in SMA type 1.””

Several other research analysts also recently commented on the stock. Zacks Investment Research raised shares of AveXis from a “hold” rating to a “buy” rating and set a $112.00 price objective for the company in a report on Tuesday, October 24th. Bank of America cut their price objective on shares of AveXis from $115.00 to $112.00 and set a “buy” rating for the company in a report on Friday, November 10th. Chardan Capital reaffirmed a “buy” rating on shares of AveXis in a report on Thursday, November 2nd. Canaccord Genuity started coverage on shares of AveXis in a report on Thursday, October 26th. They issued a “hold” rating and a $110.00 price objective for the company. Finally, BidaskClub downgraded shares of AveXis from a “hold” rating to a “sell” rating in a report on Thursday, December 14th. Three research analysts have rated the stock with a sell rating, four have assigned a hold rating and fifteen have given a buy rating to the company. AveXis has an average rating of “Buy” and an average price target of $116.95.

AveXis (NASDAQ:AVXS) traded up $2.36 on Monday, reaching $111.90. 306,673 shares of the company traded hands, compared to its average volume of 670,478. The company has a market cap of $4,020.00 and a P/E ratio of -20.05. AveXis has a 52 week low of $53.94 and a 52 week high of $128.00.

In other AveXis news, VP Sukumar Nagendran sold 1,780 shares of the firm’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $94.77, for a total value of $168,690.60. Following the completion of the transaction, the vice president now directly owns 1,780 shares of the company’s stock, valued at approximately $168,690.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Andrew F. Knudten sold 2,000 shares of the firm’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $94.48, for a total transaction of $188,960.00. Following the completion of the transaction, the vice president now directly owns 7,000 shares of the company’s stock, valued at $661,360. The disclosure for this sale can be found here. Over the last three months, insiders sold 57,560 shares of company stock valued at $6,160,062. Insiders own 18.60% of the company’s stock.

Large investors have recently made changes to their positions in the business. Strs Ohio bought a new position in AveXis in the 3rd quarter valued at $116,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in AveXis by 57.5% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,241 shares of the company’s stock valued at $137,000 after purchasing an additional 453 shares during the period. Cubist Systematic Strategies LLC boosted its holdings in AveXis by 688.6% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 1,806 shares of the company’s stock valued at $175,000 after purchasing an additional 1,577 shares during the period. Teacher Retirement System of Texas purchased a new stake in shares of AveXis during the 3rd quarter valued at $200,000. Finally, Deschutes Portfolio Strategy LLC purchased a new stake in shares of AveXis during the 3rd quarter valued at $203,000. 81.52% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This story was originally published by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was illegally stolen and republished in violation of US and international copyright and trademark legislation. The original version of this story can be read at https://www.americanbankingnews.com/2018/02/12/mizuho-begins-coverage-on-avexis-avxs.html.

About AveXis

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Analyst Recommendations for AveXis (NASDAQ:AVXS)

Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply